Liu Hangkuan, Wang Zhijia, Sun Haonan, Teng Tianming, Li Yongle, Zhou Xin, Yang Qing
Graduate School of Tianjin Medical University, Tianjin, China.
Department of Cardiology, Tianjin Medical University General Hospital, Tianjin, China.
Front Cardiovasc Med. 2021 Jan 18;7:599334. doi: 10.3389/fcvm.2020.599334. eCollection 2020.
Coronavirus disease 2019 (COVID-19), a respiratory syndrome, is a global pandemic. Therefore, there is an urgent need to explore mechanisms implicated in the pathogenesis of the disease. Clinical and autopsy studies show a complex chain of events preceding COVID-19-related death. The disease is characterized by endothelial dysfunction, platelet activation, thrombosis, coagulopathy, and multiple organ failure. Globally, millions of patients with coronary heart disease undergo percutaneous coronary intervention (PCI) each year. These patients undergo high-intensity antithrombotic therapy during hospitalization and dual antiplatelet therapy (DAPT) for at least 6 months post PCI. COVID-19 is characterized by changes in platelet counts. Treatment of ischemic events that occur during stent implantation is associated with bleeding complications in patients following PCI complicated by COVID-19. This review summarizes recent progress in activation status and levels of COVID-19-related platelet changes. These findings will provide information on the effectiveness of antithrombotic therapy for the management of platelet changes in COVID-19 patients.
2019冠状病毒病（COVID-19）是一种呼吸系统综合征，是全球大流行疾病。因此，迫切需要探索与该疾病发病机制相关的机制。临床和尸检研究显示了COVID-19相关死亡之前的一系列复杂事件。该疾病的特征是内皮功能障碍、血小板活化、血栓形成、凝血病和多器官衰竭。在全球范围内，每年有数百万冠心病患者接受经皮冠状动脉介入治疗（PCI）。这些患者在住院期间接受高强度抗血栓治疗，并在PCI术后至少6个月接受双联抗血小板治疗（DAPT）。COVID-19的特征是血小板计数发生变化。在合并COVID-19的PCI术后患者中，支架植入期间发生的缺血事件的治疗与出血并发症相关。本综述总结了COVID-19相关血小板变化的激活状态和水平的最新进展。这些发现将为抗血栓治疗对COVID-19患者血小板变化管理的有效性提供信息。
